In a new study, researchers have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.
from Top Health News -- ScienceDaily https://ift.tt/3qSwqhB
No comments:
Post a Comment